Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day
Hyderabad-based Indian multinational pharmaceutical and biotechnology company Natco Pharma’s shares were in the spotlight on Monday after it received tentative approval from the U.S. Food and Drug Administration (FDA) for Olaparib, 100 mg, and 150 mg, which are bioequivalent to AstraZeneca Pharmaceuticals’ referenced drug Lynparza used in the treatment of certain types of cancer. The…
Read More “Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day” »